With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
Hosted on MSN2d
Amgen price target lowered to $295 from $310 at CitiCiti lowered the firm’s price target on Amgen (AMGN) to $295 from $310 and keeps a Neutral rating on the shares. Ahead of the ...
Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
FFO, a key performance measure for REITs, came in at $411.8 million, or $2.39 per share, for the quarter, compared with $389.8 million, or $2.28 per share, a year ago. Its total revenue for the ...
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...
(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner ...
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback